LINC AB

Research LINC AB (6ZB) on Bullrun: valuation model: 18.6% overvalued, market cap EUR 360.20M, P/E 9.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6ZB
• ExchangeF
• CountrySweden
• SectorFinancial Services
• IndustryAsset Management
• CurrencyEUR
• Valuation signal18.6% overvalued
• Market capEUR 360.20M
• P/E9.6
• Financial periodFY2024
• Net incomeSEK 1.30B

Valuation Snapshot

Bullrun's latest valuation model marks LINC AB as 18.6% overvalued; latest market cap is EUR 360.20M; P/E is 9.6.

About LINC AB

Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies.

Frequently asked questions

Is LINC AB overvalued or undervalued?

Bullrun's valuation model currently marks LINC AB as 18.6% overvalued.

What is LINC AB's market cap?

LINC AB's market capitalization is EUR 360.20M.

What is LINC AB's P/E ratio?

LINC AB's price-to-earnings (P/E) ratio is 9.6.

What does LINC AB do?

Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies.